Anthos Therapeutics

Novartis head office
#Anthos Therapeutics #Cardiovascular disease #Mergers and acquisitions #Monoclonal antibodies #Novartis

Novartis acquires Anthos Therapeutics for $925 million

Novartis has agreed to acquire Anthos Therapeutics, a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway.  Abelacimab is currently in Phase III development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation. … Read More

#Business & Investment #News #Trending News